The rise of GLP-1 weight loss drugs has been a fast-moving phenomenon that echoes the early days of PD-1 inhibitors in cancer immunotherapy. Both therapies emerged from years of clinical research, captured widespread attention, and generated significant market potential. However, industry experts caution that despite the similarities in their rapid ascent, key differences in market dynamics may prevent history from repeating itself.
The Early Days of GLP-1 Drugs: A Familiar Pattern
The journey of GLP-1 therapies, such as Ozempic and Wegovy, closely mirrors that of PD-1 inhibitors. These breakthrough drugs, initially developed for other purposes (such as diabetes in the case of Ozempic), quickly found their place in weight loss treatments. Like PD-1 inhibitors—used in cancer therapies—these weight loss drugs have drawn widespread interest, with early market leaders Eli Lilly and Novo Nordisk raking in billions. But, as with PD-1 inhibitors, the race for dominance in this space is only beginning, and the flood of competitors entering the GLP-1 market could ultimately shape its future in unexpected ways.
Parallels with PD-1 Inhibitors
The rise of PD-1 inhibitors in cancer treatment serves as a warning sign for fast-followers in the GLP-1 space. Keytruda, Merck’s PD-1 drug, was first approved in 2014, followed by Opdivo from Bristol Myers Squibb. Early on, Opdivo had the edge in terms of broader indications and larger sales, but over time, Keytruda overtook it, becoming the top-selling cancer treatment worldwide by 2024. Opdivo still performs well, but its sales lag behind Keytruda, illustrating how difficult it is to compete with an early market leader in such a specialized field.
The same situation could play out in the GLP-1 space. With Eli Lilly’s Wegovy and Novo Nordisk’s Ozempic capturing the lion’s share of the weight loss market, it will be a monumental challenge for later-stage entrants to catch up. While there’s room for smaller players to carve out market niches (as seen with Tecentriq and Imfinzi in the PD-1 market), the question remains whether fast-followers will be successful in creating therapies that can truly challenge the dominant players.
The Risk of Being a Fast-Follower
As the PD-1 space demonstrated, not all companies betting on being the second or third drug to market succeeded. Drugs such as Bavencio and Tevimbra, developed by Pfizer and Novartis, respectively, struggled to make a mark, despite backing from big pharma. This highlights the harsh reality that being a fast-follower in the pharmaceutical industry doesn’t guarantee success.
For smaller companies or newer entrants looking to capitalize on the GLP-1 boom, the risks are high. Developing a differentiated product—whether through improved efficacy, better tolerability, or unique formulations—will be key to carving out a space. Without these differentiating factors, many companies may fall short of competing with the industry giants.
GLP-1 vs. PD-1: Key Market Differences
While the PD-1 market was driven by the urgent medical need to treat cancer, the GLP-1 market is largely consumer-driven. People seeking weight loss solutions are often looking for a solution to a chronic, non-life-threatening condition. This lower perceived medical necessity means that paying for weight loss treatments is subject to more scrutiny and could face challenges from insurance companies or consumers seeking discounts.
Additionally, the issue of patient churn presents another obstacle. Most GLP-1 users will stop treatment within the first year, and that figure declines even further after two years. In contrast, patients undergoing PD-1 therapies were often facing no other viable treatment options, meaning they would stay on course due to the life-or-death nature of cancer. This presents a significant hurdle for GLP-1 drug developers, who may struggle to maintain long-term patient adherence.
Patient Retention: A Major Challenge for GLP-1s
One of the key differentiators between the PD-1 and GLP-1 markets is patient retention. For cancer patients, the urgency of treatment means patients are likely to stay on their course despite potential side effects. In contrast, weight loss drugs often face a high level of drop-off after the first year, as many users find it difficult to continue long-term use. This has raised concerns about whether the GLP-1 market can sustain its current growth rates. Some analysts, including Matt Phipps from William Blair, are skeptical that sales will reach the high projections of $150 billion by the early 2030s, due to the challenges of patient retention.
Expanding Indications: A Strategy to Extend Lifespan
Both PD-1 inhibitors and GLP-1 drugs are pursuing label expansions to increase their revenue potential. Just as Keytruda has expanded to treat nearly 50 different types of cancer, GLP-1 drugs are being repurposed for additional uses. For instance, Novo Nordisk’s Wegovy has received approval for reducing cardiovascular risk, while Lilly’s Wegovy has been approved for treating obstructive sleep apnea. Future indications could include Alzheimer’s disease, kidney disease, and alcohol use disorder.
This strategy of expanding drug indications could prolong the market life of GLP-1 therapies, though the overall market for weight loss is more limited than oncology, which offers a broader range of indications.
Looking Ahead: What Will Set Successful GLP-1 Drugs Apart?
For investors and developers in the GLP-1 space, success may depend on several key factors:
Improved Efficacy: As with PD-1 inhibitors, the ability to offer superior weight loss results will likely appeal to patients looking for a more effective solution.
Better Tolerability: If GLP-1 drugs can become more tolerable, with fewer side effects, it may increase patient retention.
Small Molecule Formulations: Oral GLP-1 formulations or other innovations could give a competitor an edge over the current injectable versions.
The complexity of developing a differentiated product in the GLP-1 space may limit the appeal of investing in this market, at least in the short term. The race to create a me-too treatment has not been as compelling as in earlier stages of PD-1 development, where it was more about getting into the market quickly.
Conclusion: A Market in the Early Stages
While the boom in GLP-1 drugs has been nothing short of meteoric, experts warn that it is still in its early innings. With challenges like patient retention, pricing pressures, and the looming possibility of competition from smaller players, the market may not experience the same explosive growth that some analysts are predicting. However, the potential remains high for those companies that can successfully navigate the evolving landscape of weight-loss treatments, much like the journey of PD-1 inhibitors in oncology.
Related Topics:
Can Weight Loss Injections Cause Blood Clots
